Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2021 · 10-Q
Revenue—
Net Income-$7.67M-$7.67MN/M vs Q3 2020 EPS Diluted-$0.42-$0.42N/M vs Q3 2020 Operating Income-$7,728,000N/M Operating Cash Flowderived-$11,470,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,531,000N/M ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end